Beyond Medtech: Healthcare + Expo Taiwan Sets New Stage for Global Innovation in Future AI Healthcare
The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape of AI healthcare on a global scale. This year's edition boasts the remarkable participation of 650 companies, occupying 2,300 booths, and has garnered the attention of leading technology firms and hospitals across the Asia-Pacific region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201062013/en/
Expand businesses into growing markets in the APAC region with Healthcare+ Expo Taiwan. Join medical institutes and companies in the fields of medtech, biotech and healthcare to promote products, build partnerships and seize supply-demand opportunities. (Graphic: RBMP & IBMI)
Taiwan's pivotal role in the AI-related supply chain is underscored by its impressive contribution, manufacturing AI chips, and over 90% of the world's AI servers. This proficiency positions Taiwan as a key player in driving substantial computing power, establishing it as an indispensable global collaborator in the realm of AI healthcare. The Expo is showcasing an extensive array of AI applications and solutions, encompassing AI infrastructure, cloud and high-performance computing servers, AI-enabled medical devices and diagnostics, and generative AI for workflow optimization. Participating medical centers from Taiwan, together with their IT/ICT sector partners and multinational giants such as Intel and Microsoft, aim to address healthcare challenges and foster interdisciplinary collaborations.
Anticipating the attendance of over 30,000 professionals from the Asia-Pacific region, Eastern Europe, and the Gulf, the organizer foresees substantial interest from industry associations in the United Arab Emirates, Poland, Czech Republic, as well as rapidly growing economies such as Malaysia, Philippines, Indonesia, Vietnam, and Thailand. Strategic partnerships with Taiwan's healthcare industry are in the spotlight, with more than 500 scheduled B2B meetings designed to facilitate trade discussions and catalyze new business ventures.
Distinguishing itself as the only trade fair globally with a focus on hospitals, Healthcare+ Expo has experienced consistent annual growth of 15% in event scale over its seven-year history. It has evolved into one of the most sought-after gatherings in the Asia-Pacific region for healthcare professionals. Concurrently, the Expo is hosting major events, including the MEDTEX Summit Asia and the Cancer Treatment and Precision Medicine in APAC forum.
The Healthcare+ Expo 2024 is scheduled for December 5 to 8, 2024, and will continue to serve as a catalyst for transformative advancements and collaborative breakthroughs in the ever-evolving landscape of AI healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Institute for Biotechnology and Medicine Industry (IBMI); Research Centre for Biotechnology and Medicine Policy (RBMP)
Yu Chen (Katy) Chu, Project Manager
886 2 2655 7888 ext.627
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS to Launch an Infrastructure Region in Mexico26.2.2024 15:50:00 CET | Press release
Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today announced plans to launch an AWS infrastructure Region in Mexico by early 2025. The new AWS Mexico (Central) Region will give developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, greater choice for running their applications and serving end users from data centers located in Mexico, ensuring that customers who want to store their content in Mexico can do so. As part of its long-term commitment to Latin America, AWS is planning to invest more than $5 billion (approx. MXN $85 billion) in Mexico over 15 years. The upcoming AWS Mexico Region is the latest in AWS’s ongoing investments in Mexico to provide customers with advanced and secure cloud technologies. For more information about AWS Global Infrastructure, visit aws.amazon.com/about-aws/global-infrastructure. “Cloud services are an essential part of everyday life, helping us to digitally and econo
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair26.2.2024 15:19:00 CET | Press release
Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma). Dr. Donnenfeld joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® canalicular gel. The FDA-cleared hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system. “Nordic Pharma continues to build a world class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S. as we prepare to bring LACRIFILL to market. With over 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and catarac
Adtran recognized among STL Partners’ top 100 edge computing companies for 202426.2.2024 14:00:00 CET | Press release
Adtran today announced that it has been recognized as one of STL Partners’ top 100 edge computing companies for 2024, marking its second consecutive year of inclusion on the list. The acknowledgment reaffirms Adtran’s substantial contributions to the sector and highlights its role as a leader, driving innovation amidst the quickly evolving edge computing landscape. This leadership is increasingly vital as more enterprises and service providers seek options beyond centrally deployed, hyperscale clouds to support their business requirements of reducing hosting and backhaul costs, improving service performance and security, and accelerating time to market. This is especially true for the next wave of AI and IoT applications being deployed in various industries, such as manufacturing, transportation, logistics, healthcare, finance, media, retail and the public sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226247955/e
Vantage Data Centers Names Two New Regional Presidents to Support Market Growth Amidst Booming Cloud and AI Demand26.2.2024 14:00:00 CET | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced the appointments of Dana Adams and David Howson who will serve as regional presidents of North America and EMEA, respectively. The company also announced that Antoine Boniface, who has served as president of EMEA for the past four years, will take on a new role as chief commercial officer for the region. These appointments come as the company enters 2024 positioned for another year of significant growth and expansion across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226667521/en/ Dana Adams has joined Vantage Data Centers as President, North America. (Photo: Business Wire) Adams joins Vantage’s executive leadership team as president of North America, bringing nearly 18 years of experience in the data center sector to the company. Based in Denver, she will oversee the region’s growth, including market developm
Pulmonx Announces Treatment of the First Patient with the AeriSeal ® System in CONVERT II Pivotal Trial26.2.2024 14:00:00 CET | Press release
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the treatment of the first patient in the CONVERT II Pivotal Trial, a multicenter, international study evaluating the safety and effectiveness of the AeriSeal® System in limiting collateral ventilation in severe COPD/emphysema patients. Collateral ventilation is caused by openings in the lung fissures, or walls between the lung lobes. The AeriSeal System is designed to occlude these naturally occurring openings in a lobe targeted for bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. Successful treatment with the AeriSeal System is followed by treatment with commercially available Zephyr® Valves. Pulmonx received a staged IDE approval by the Food and Drug Administration (FDA) to commence the CONVERT II Pivotal Trial for the AeriSeal System in late 2023. The goal of the CONVERT II Piv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom